Drug Trial Radar · NCT02503774
MEDI9447 Alone and in Combination With MEDI4736 in Adult Participants With Select Advanced Solid Tumors.
Last checked: Nov 19, 2026Latest source record: Jul 11, 2023 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
192
Actual
Start
Jul 24, 2015
Primary completion
Jan 22, 2021
Study completion Mar 7, 2023
Sponsor
- Lead sponsor
- MedImmune LLCAstraZeneca (AZN)
- Sponsor type
- Industry
- First posted
- Jul 21, 2015
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Non randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years, up to 101 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The purpose of this study is to Evaluate the Safety, Tolerability, Pharmacokinetics, Immunogenicity, and Antitumor Activity of MEDI9447 Alone and in Combination with MEDI4736 in Adult Participants with Select Advanced Solid Tumors
Conditions
- Solid Tumors
Interventions
OleclumabDrug
Participants will receive IV infusion of oleclumab as stated in arms' description.
DurvalumabDrug
Participants will receive IV infusion of durvalumab as stated in arms' description.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Number of Participants With Dose Limiting Toxicities (DLTs) in Dose-escalation PhaseTime frame: From Day 1 to Day 28 after first dose of study drug
- Number of Participants With Treatment Emergent Adverse Events (TEAEs) and Treatment Emergent Serious Adverse Events (TESAEs)Time frame: From Day 1 through 200.1 weeks (corresponding to maximum observed duration)
- Number of Participants With Abnormal Clinical Laboratory Parameters Reported as TEAEsTime frame: From Day 1 through 200.1 weeks (corresponding to maximum observed duration)
- Number of Participants With Abnormal Vital Signs Reported as TEAEsTime frame: From Day 1 through 188.1 weeks (corresponding to maximum observed duration)
- Number of Participants With Change From Baseline in QTcFTime frame: Baseline (prior to Day 1 dose) through 188.1 weeks (corresponding to maximum observed duration)
Locations
18 sites in 3 countries. Site status is shown where the registry gives one.
Research Site
La Jolla, California
Research Site
New Haven, Connecticut
Research Site
Gainesville, Florida
Research Site
Atlanta, Georgia
Research Site
St Louis, Missouri
Research Site
Durham, North Carolina
Research Site
Cincinnati, Ohio
Research Site
Columbus, Ohio
Research Site
Nashville, Tennessee
Research Site
Dallas, Texas
Research Site
Houston, Texas
Research Site
Camperdown, Australia
Research Site
Parkville, Australia
Research Site
St Leonards, Australia
Research Site
Woolloongabba, Australia
Research Site
Seoul, South Korea
Research Site
Seoul, South Korea
Research Site
Seoul, South Korea
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.